within Pharmacolibrary.Drugs.ATC.S;

model S01GX13
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.606,
    Cl             = 6.5e-06,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0012900000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.015000000000000001,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.0005899999999999999,
    k12             = 0.25,
    k21             = 0.25
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01GX13</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Bilastine is a second-generation non-sedating antihistamine used for the treatment of allergic rhinoconjunctivitis and urticaria in adults and children over 12 years; it is approved and in clinical use today in Europe and other regions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after oral administration of bilastine 20 mg as a single dose, under fasting conditions.</p><h4>References</h4><ol><li><p>Sádaba, B, et al., &amp; Valiente, R (2013). Oral availability of bilastine. <i>Clinical drug investigation</i> 33(5) 375–381. DOI:<a href=\"https://doi.org/10.1007/s40261-013-0076-y\">10.1007/s40261-013-0076-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23529786/\">https://pubmed.ncbi.nlm.nih.gov/23529786</a></p></li><li><p>Ochoa, D, et al., &amp; Fernández, N (2021). Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation. <i>Advances in therapy</i> 38(7) 4070–4081. DOI:<a href=\"https://doi.org/10.1007/s12325-021-01801-y\">10.1007/s12325-021-01801-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34125400/\">https://pubmed.ncbi.nlm.nih.gov/34125400</a></p></li><li><p>Majorek-Olechowska, B, et al., &amp; Arranz, P (2024). Pharmacokinetics and Safety of Bilastine 10 mg/d in Children Aged 2 to 5 Years With Allergic Rhinoconjunctivitis or Urticaria: A Phase 3 Clinical Trial. <i>Journal of investigational allergology &amp; clinical immunology</i> None 0–None. DOI:<a href=\"https://doi.org/10.18176/jiaci.1003\">10.18176/jiaci.1003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38725318/\">https://pubmed.ncbi.nlm.nih.gov/38725318</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01GX13;
